Multiple Sclerosis Management During the COVID-19 Pandemic

Area of Science:

• Neurology
• Infectious Diseases
• Immunology

Background:

• COVID-19 presents unique challenges for multiple sclerosis (MS) patient care.
• Guidelines for managing MS during the pandemic required continuous updates.
• Understanding the interplay between MS, COVID-19, and treatments is crucial.

Purpose of the Study:

• To review the literature on COVID-19 in relation to multiple sclerosis (MS) clinical management over the first two years of the pandemic.
• To assess the impact of MS on COVID-19 risk and the influence of disease-modifying therapies (DMTs).
• To explore COVID-19's potential effects on MS and considerations for DMTs and vaccination.

Main Methods:

• Literature review of scientific articles published within the first two years of the COVID-19 pandemic.
• Analysis of studies focusing on COVID-19 risk in MS patients.
• Evaluation of the role of disease-modifying therapies (DMTs) and vaccination in MS management during the pandemic.

Main Results:

• Most MS patients do not require significant treatment plan changes due to COVID-19.
• Older, more disabled MS patients on potent therapies may need risk-reduction strategies.
• Further research is needed on the long-term impacts of COVID-19 on MS and treatment interactions.

Conclusions:

• The pandemic necessitated re-evaluation of MS management priorities.
• Individualized risk assessment is key for MS patients, especially those with comorbidities or on specific DMTs.
• Continued research into infection-DMT-MS interactions is vital for optimizing patient care.